Combined Molecular and Mechanistic Methods for Detection of Pressure Ulcers
- Conditions
- Pressure UlcerInflammatory Response
- Interventions
- Procedure: non-invasive ventilation teraphy, NIV
- Registration Number
- NCT06468306
- Lead Sponsor
- Linkoeping University
- Brief Summary
This project aims to develop a novel method for identifying early tissue damage related to pressure ulcer (PU) development in vulnerable patients by measuring biomarkers of inflammation on the skin surface. PUs are common and costly injuries that result from prolonged pressure on the skin. Current methods to assess PU risk are unreliable, and the mechanisms of PU development are not well understood. This project contributes to new knowledge of PU etiology as well as the individual variability at a molecular level combined with new knowledge about nursing actions and clinical factors linked to PU progression and outcomes of prevention. The project will use non-invasive techniques and model-based analysis to identify specific biomolecules that reflect individual susceptibility to pressure exposure in different PU risk scenarios.
- Detailed Description
Purpose and aims A pressure ulcer (PU) is a localized injury to the skin and/or underlying tissue and develop from prolonged pressure on the skin. Such injuries are common in the healthcare setting, especially among vulnerable elderly. PUs greatly decrease the quality of life of individuals and are costly for the healthcare system. As many as 14% of the inpatients suffered from PUs in the Swedish country's municipalities and regions during 2022. The origin and timing of events leading to PUs are not fully understood, and current methods to assess the risk for an individual to develop a PU, are unreliable. Therefore, there is an urgent need to develop more objective, sensitive and specific methods for identifying early signs of tissue damage before they come visible and thus avoid development of PUs.
The investigators have previously identified a preliminary set of molecular biomarkers (cytokines and proteins), sampled non-invasively in the sebum, that reflects the inflammatory process under-pinning PU etiology and, possibly, individual susceptibility to pressure exposure. Therefore, it is hypothesize that non-invasive measurements of specific biomolecules on the skin surface, together with model-based analysis, can be used for individualized PU prediction. Accordingly, the purpose of this project is to confirm and expand on these preliminary findings in different PU risk scenarios to model the underlying inflammatory processes that reflect the individual vulnerability of the skin caused by pressure exposure and use modeling to extract a new layer of mechanistic insights of the underlying inflammatory process in different patient populations.
The specific aims of the project are:
1. To establish and validate optimal combinations of molecular biomarkers to identify individual susceptibility to pressure exposure during routine management regimes related to medical devises non-invasive ventilation (NIV) therapy.
2. To unravel key mechanisms in inflammatory processes related to early tissue damage by developing a mathematical model for the timing of events in the response to pressure, based on collected biomolecules, earlier data, and interaction databases
3. To identify risk factors of PU vulnerability on an individual level in routine clinical settings by combining biomolecules, model-based simulations, and clinical parameters
Recruitment & Eligibility
- Status
- NOT_YET_RECRUITING
- Sex
- All
- Target Recruitment
- 150
- patients that use oronasal face masks in their ordinary care during routine management regimes of non invasive ventilation.
Exclusion Criteria
- acute respiratory failure
- previous ICU care
- pressure ulcer on measurement site
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description individuals with NIV treatment non-invasive ventilation teraphy, NIV Patients that use oronasal face masks in their ordinary care to measure early-stage medical devise-related tissue damage during routine management regimes of NIV. Approximately 150 adult patients of both sexes will be recruited, from facilities that employ oronasal face masks in the routine care.
- Primary Outcome Measures
Name Time Method GM-CSF 2 minutes inflammatory biomarker
GRO-alpha 2 minutes inflammatory biomarker
I-309 2 minutes inflammatory biomarker
IL-2 2 minutes inflammatory biomarker
IL-27 2 minutes inflammatory biomarker
IL-3 2 minutes inflammatory biomarker
IL-31 2 minutes inflammatory biomarker
IL-9 2 minutes inflammatory biomarker
MIP-1α 2 minutes inflammatory biomarker
ENA-78 2 minutes inflammatory biomarker
IFN-α2a 2 minutes inflammatory biomarker
IFN-γ 2 minutes inflammatory biomarker
IL-15 2 minutes inflammatory biomarker
IL-17E/IL-25 2 minutes inflammatory biomarker
IL-23 2 minutes inflammatory biomarker
IL-7 2 minutes inflammatory biomarker
CTACK 2 minutes inflammatory biomarker
Eotaxin 2 minutes inflammatory biomarker
FLT3L 2 minutes inflammatory biomarker
Fractalkine 2 minutes inflammatory biomarker
Eotaxin-2 2 minutes inflammatory biomarker
IL-17A 2 minutes inflammatory biomarker
IL-17A/F 2 minutes inflammatory biomarker
IL-17C 2 minutes inflammatory biomarker
IL-22 2 minutes inflammatory biomarker
IL-4 2 minutes inflammatory biomarker
IP-10 2 minutes inflammatory biomarker
MCP-1 2 minutes inflammatory biomarker
MCP-3 2 minutes inflammatory biomarker
TNF-α 2 minutes inflammatory biomarker
Eotaxin-3 2 minutes inflammatory biomarker
EPO 2 minutes inflammatory biomarker
IL-10 2 minutes inflammatory biomarker
IL-12/IL-23p40 2 minutes inflammatory biomarker
IL-12p70 2 minutes inflammatory biomarker
IL-13 2 minutes inflammatory biomarker
IL-16 2 minutes inflammatory biomarker
IL-17B 2 minutes inflammatory biomarker
IL-17D 2 minutes inflammatory biomarker
IL-17F 2 minutes inflammatory biomarker
IL-18 2 minutes inflammatory biomarker
IL-1RA 2 minutes inflammatory biomarker
IL-1α 2 minutes inflammatory biomarker
IL-1β 2 minutes inflammatory biomarker
IL-33 2 minutes inflammatory biomarker
IL-5 2 minutes inflammatory biomarker
MCP-4 2 minutes inflammatory biomarker
M-CSF 2 minutes inflammatory biomarker
MDC 2 minutes inflammatory biomarker
MIF 2 minutes inflammatory biomarker
MIP-3β 2 minutes inflammatory biomarker
SDF-1alpha 2 minutes inflammatory biomarker
MIP-1β 2 minutes inflammatory biomarker
MIP-5 2 minutes inflammatory biomarker
TRAIL 2 minutes inflammatory biomarker
TSLP 2 minutes inflammatory biomarker
VEGF-A 2 minutes inflammatory biomarker
IL-8 2 minutes inflammatory biomarker
G-CSF 2 minutes inflammatory biomarker
IFN-β 2 minutes inflammatory biomarker
IL-21 2 minutes inflammatory biomarker
IL-29/IFN-L1 2 minutes inflammatory biomarker
IL-2Ra 2 minutes inflammatory biomarker
IL-6 2 minutes inflammatory biomarker
I-TAC 2 minutes inflammatory biomarker
MCP-2 2 minutes inflammatory biomarker
MIP-3α 2 minutes inflammatory biomarker
TARC 2 minutes inflammatory biomarker
TNF-β 2 minutes inflammatory biomarker
TPO 2 minutes inflammatory biomarker
YKL-40 2 minutes inflammatory biomarker
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Linköping University
🇸🇪Linköping, Sweden